GLPwatch
Papers (10588)
Page 155 of 177, ranked by citation count.
- Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
- Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes.
- Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE<sup>-/-</sup> mice.
- An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.
- A Fluorescent Probe-Based Platform for Precise Pharmaceutical Analysis and Quality Assessment of Tirzepatide.
- Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.
- Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.
- Liraglutide Potently Protects Against Streptozotocin-Induced Islet Injury Associated with Inhibition of HMGB1 Release.
- RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.
- ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
- Complete Skin Remission of Lichen Planus With Tirzepatide.
- Two Trials of Therapeutics for MASH with Liver Fibrosis.
- Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report.
- Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.
- Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights.
- Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.
- Reprint of: Impact of a pharmacist-led weight management service in a cardiology clinic.
- Glucagon-like peptide-1 receptor (GLP-1R) agonists prevent tributyltin-induced muscle atrophy/wasting via restoring GLP-1R signaling in vitro and in mice.
- Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?
- GLPs Significantly Decrease the Risk of Postoperative Surgical Complications: A TriNetX Retrospective Cohort Study.
- Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
- [Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?]
- Illeum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.
- Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.
- Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real-World Evidence From the REALISED Study.
- Dulaglutide efficacy.
- Simultaneous Versus Sequential Initiation of Lixisenatide and Basal Insulin for Type 2 Diabetes: Subgroup Analysis of a Japanese Post-Marketing Surveillance Study of Lixisenatide (PRANDIAL).
- REWIND Diabetes for Octogenarians.
- Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
- Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs.
- Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model.
- Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.
- Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.
- Initium novum?
- Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide.
- Impact of Tirzepatide on FIB-4 in Patients with Type 2 Diabetes: A Comparison between GLP-1RA-naïve and GLP-1RA Switch Initiation in a Retrospective Cohort.
- From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.
- Correction: Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.
- Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.
- Comparison table: Some drugs for weight management.
- Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.
- Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.
- [Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day].
- Use of semaglutide after acute coronary syndrome: an exploratory retrospective study.
- [Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults].
- Lead-guided prodrug development of small molecules as GLP-1R agonists.
- Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.
- Reply to "Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications".
- Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications.
- Correction: Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
- Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.
- Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus.
- Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.
- Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
- Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?
- Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide.
- Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.
- [In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.]
- EBM BLS: Tirzepatide Remains Effective for Obesity Treatment and Diabetes Prevention at 3 Years of Follow-up.